MYASTERIX Phase 1b clinical study is launched to test a therapeutic vaccine for Myasthenia Gravis.
Rixensart, Belgium, December 23, 2015 - The MYASTERIX consortium has launched the Phase 1b clinical trial of an innovative antigen specific treatment that aims to provide significant and lasting improvement of myasthenia gravis (MG). The study will evaluate the safety, immunogenicity, and also explore the efficacy of a therapeutic vaccine candidate (coded CV-MG01) with designated orphan drug status in the USA and Europe by the FDA and the EMA. CV-MG01 comprises two synthetic complementary peptides conjugated to a carrier protein. The MYASTERIX trial is sponsored by CuraVac Europe, a company based in Belgium and conducted at the Antwerp University Hospital (Belgium) in collaboration with the Leiden University Medical Center (the Netherlands), Aepodia (Belgium & France), piCHEM (Austria) and Inserm Transfert (France). This trial is a major milestone for the MYASTERIX project funded by the European Union’s Seventh Framework Programme.
Following their success at ENTENTE, Curavac went on to receive a prize for best presentation at the European Venture Contest in Dusseldorf on 9-10 December 2014. For more information: http://www.e-unlimited.com/events/awards_winners.aspx?events_id=589